Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Increases By 16.5%

Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 577,700 shares, a growth of 16.5% from the December 15th total of 496,000 shares. Approximately 1.5% of the company's shares are sold short. Based on an average trading volume of 255,900 shares, the short-interest ratio is currently 2.3 days.

Kronos Bio Stock Down 1.9 %

Shares of Kronos Bio stock traded down $0.02 during trading hours on Friday, hitting $0.99. The company's stock had a trading volume of 43,891 shares, compared to its average volume of 296,299. The company has a market capitalization of $59.77 million, a PE ratio of -0.69 and a beta of 1.79. The business has a fifty day moving average of $0.95 and a 200 day moving average of $1.02. Kronos Bio has a 1-year low of $0.69 and a 1-year high of $1.60.

Wall Street Analysts Forecast Growth

KRON has been the topic of several research reports. Piper Sandler lowered Kronos Bio from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $6.00 to $1.00 in a research report on Thursday, November 14th. TD Cowen downgraded Kronos Bio from a "buy" rating to a "hold" rating in a report on Thursday, November 14th.

Institutional Investors Weigh In On Kronos Bio

An institutional investor recently raised its position in Kronos Bio stock. Forefront Analytics LLC boosted its stake in Kronos Bio, Inc. (NASDAQ:KRON - Free Report) by 75.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 134,998 shares of the company's stock after acquiring an additional 57,867 shares during the quarter. Forefront Analytics LLC owned about 0.22% of Kronos Bio worth $167,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 64.09% of the company's stock.

Kronos Bio Company Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.